We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+31.8%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$215M
AUM Growth
+$73.1M
Cap. Flow
+$46.9M
Cap. Flow %
21.76%
Top 10 Hldgs %
95.46%
Holding
17
New
2
Increased
3
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$75.2M
2
IRTC icon
iRhythm Holdings
IRTC
+$1.71M
3
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$701K
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$229K
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$79.4K

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$25.3M
2
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$2.32M
3
SAGE
Sage Therapeutics
SAGE
+$1.81M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$1.63M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$77.9M 36.17%
+4,104,140
New +$75.2M
IRTC icon
2
iRhythm Holdings
IRTC
$3.59B
$36.5M 16.94%
703,741
+37,776
+6% +$1.71M
PDSB icon
3
PDS Biotechnology
PDSB
$38.4M
$25.2M 11.68%
117,243
– –
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$14.3M 6.65%
852,497
-100,000
-10% -$1.63M
WVE icon
5
Wave Life Sciences
WVE
$1.12B
$14.3M 6.64%
658,259
– –
DMTX
6
DELISTED
Dimension Therapeutics, Inc
DMTX
$12.4M 5.73%
2,059,283
– –
CRSP icon
7
CRISPR Therapeutics
CRSP
$4.58B
$9.43M 4.38%
527,730
– –
AVEO
8
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$8.54M 3.96%
234,067
-75,000
-24% -$2.32M
SRRA
9
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.34M 2.01%
69,956
+1,354
+2% +$79.4K
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$2.8M 1.3%
44,872
-23,000
-34% -$1.81M
OBSV
11
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.12M 0.98%
260,301
+30,096
+13% +$229K
ALDR
12
DELISTED
Alder Biopharmaceuticals
ALDR
$2.1M 0.97%
171,364
– –
TRIL
13
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.08M 0.97%
404,159
– –
DERM
14
DELISTED
Dermira, Inc.
DERM
$1.65M 0.77%
61,109
– –
MRNS
15
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.47M 0.68%
+62,500
New +$701K
OTIC
16
DELISTED
Otonomy, Inc.
OTIC
$357K 0.17%
109,825
– –
ARAV
17
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-241,383
Closed -$25.3M

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q3 2017 Portfolio in Review

As of Q3 2017, New Leaf Venture Partners held 17 positions worth $215M, up 51% from $142M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

New Leaf Venture Partners deployed $46.9M of net new capital in Q3 2017, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Deciphera Pharmaceuticals, Inc. Common Stock: 4,104,140 shares worth $77.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was AVEO Pharmaceuticals, Inc., an estimated $2.32M trimmed.

  • New Leaf Venture Partners's largest Q3 2017 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 4,104,140 shares worth $77.9M.
  • New Leaf Venture Partners added most to iRhythm Holdings in Q3 2017, an estimated $1.71M increase.
  • New Leaf Venture Partners's biggest Q3 2017 reduction was AVEO Pharmaceuticals, Inc., cutting an estimated $2.32M.
  • New Leaf Venture Partners fully exited Aravive, Inc. Common Stock in Q3 2017, selling an estimated $25.3M.
  • New Leaf Venture Partners's ten largest holdings make up 95% of its $215M portfolio in Q3 2017.
  • New Leaf Venture Partners opened 2 new positions and closed 1 in Q3 2017.
  • New Leaf Venture Partners's portfolio value rose 51% quarter-over-quarter to $215M.

Based on New Leaf Venture Partners's 13F filing for Q3 2017, filed 14 Nov 2017.